Comment on 4 Biggest HIV Drugs of 2024: Which Stocks Are Poised to Profit?

4 Biggest HIV Drugs of 2024: Which Stocks Are Poised to Profit?

Seventeen in '17. It might sound like a slogan, but it's actually a reference to the size of the global HIV drug market. In 2017, the HIV market topped $17 billion, according to data from market research firm IMARC Group. The best-selling HIV drugs last year were Genvoya, Triumeq, Truvada, Tivicay, and Atripla.

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News